T-cell non-Hodgkin’s lymphoma (T-NHL) is rare and heterogeneous disease. There is a marked difference in biology, clinical presentation and therapeutic outcomes worldwide. This is a retrospective study from May 2014 to May 2018. Patients with established T-NHL after diagnosis were included, and their clinical presentation and therapeutic outcomes were analysed in detail. In the above-mentioned period, a total of 248 NHL patients were evaluated out of which 32(12.9%) had T-NHL. The median age of presentation was 37 years (range 7–69 years), with a male predominance 26 (81.2%). Most common presentation was painless lymphadenopathy 18 (56.2%). B symptoms were found in 8 (25%). In the Ann Arbor staging system, most T-NHL presented with either Stage III or IV with 12 (37.5%) patients respectively. Among the T-NHL subtypes, peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), 20 (62.5%); anaplastic large-cell lymphoma (ALCL), 7 (21.9%); angioimmunoblastic T-cell lymphoma (AITL), 3 (9.4%); cutaneous T-cell lymphoma (CTCL), 2 (6.2%); and prolymphocytic leukaemia (PLL), 1 (3.1%) were diagnosed. Therapeutic options for T-NHL used were cyclophosphamide, doxorubicin, vincristine, prednisolone and etoposide (CHOEP) based. Response assessment after 6 cycles showed complete response (CR) and partial response (PR), 13 (40.6%) and 16 (50%), respectively. Three patients died during therapy. The progression-free survival (PFS) at 18 months was 57.34%. In our study, 12.9% patients had T- NHL among all patients of lymphoma. Lymphadenopathy and advanced stage disease were most common presentations. Chemotherapy outcomes showed CR in 40.6% of patients and PFS at 18 months was 57.34%.

中文翻译：

---

T细胞淋巴瘤：印度东部一家三级医院的临床表现和治疗结果

T细胞非霍奇金淋巴瘤（T-NHL）是罕见的异质性疾病。全球生物学，临床表现和治疗结果均存在明显差异。这是一项从2014年5月至2018年5月的回顾性研究。纳入了诊断后已建立T-NHL的患者，并对他们的临床表现和治疗结果进行了详细分析。在上述期间，总共评估了248位NHL患者，其中32位（12.9％）患有T-NHL。报告的中位年龄为37岁（7-69岁），其中男性占26位（81.2％）。最常见的表现为无痛性淋巴结病18（56.2％）。在8（25％）中发现B症状。在Ann Arbor分期系统中，大多数T-NHL分别处于III期或IV期，分别有12名（37.5％）患者。在T-NHL亚型中，未另作说明的外周T细胞淋巴瘤（PTCL，NOS）为20（62.5％）。间变性大细胞淋巴瘤（ALCL），7（21.9％）；血管免疫母细胞性T细胞淋巴瘤（AITL），3（9.4％）；皮肤T细胞淋巴瘤（CTCL），2（6.2％）; 和淋巴细胞白血病（PLL），诊断为1（3.1％）。使用的T-NHL的治疗选择是基于环磷酰胺，阿霉素，长春新碱，泼尼松龙和依托泊苷（CHOEP）。6个周期后的反应评估显示完全反应（CR）和部分反应（PR），分别为13（40.6％）和16（50％）。三名患者在治疗期间死亡。18个月的无进展生存期（PFS）为57.34％。在我们的研究中，所有淋巴瘤患者中有12.9％的患者患有T-NHL。淋巴结肿大和晚期疾病是最常见的表现。化疗结果显示，CR的患者为40.6％，PFS在18个月时为57.34％。